VYNDAQEL caps moll 20 mg 30 pce

7680670830010 CH-67083 N07XX08 01.99.0.
VYNDAQEL caps moll 20 mg 30 pce
VYNDAQEL caps moll 20 mg 30 pce
VYNDAQEL caps moll 20 mg 30 pce
1 / 3
google

Details

Product number
6708301
CPT
-
Packaging group
30
Unit
Kapsel(n)
Composition
tafamidisum megluminum 20 mg corresp. tafamidisum 12.2 mg, macrogolum 400, polysorbatum 80, sorbitani oleas, Kapselhülle: gelatina, glycerolum, sorbitolum liquidum partim deshydricum corresp. sorbitolum max. 44 mg, E 172 (flavum), E 171, Drucktinte: macrogolum 400, propylenglycolum, polyvinylis acetas phtalas, E 120, E 133, pro capsula.

Articles (1)

Vyndaqel 20 mg, Weichkapseln
Weichkapseln
30
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
16/04/2025
Patient information leaflet
Français
16/04/2025
Patient information leaflet
Italien
16/04/2025
Professional SmPC
Allemand
16/04/2025
Professional SmPC
Français
16/04/2025
Professional SmPC
Italien
16/04/2025

Detailed composition

Substance Quantity Type Category
(N/A)
20.0 MG Substance WIZUS
(N/A)
12.2 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HBESI
(N/A)
- Substance FTODK
(N/A)
- Substance FNIDK
(N/A)
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
(N/A)
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
(N/A)
- Substance HNIDK
(N/A)
- Substance FIMDK
(N/A)
- Substance FIMDK

Authorization holder

Pfizer AG

8052 Zürich

Authorization information

Swissmedic authorization number
67083
Drug name
Vyndaqel 20 mg, Weichkapseln
Galenic form
KAPWE
ATC Code
N07XX08
Authorization status
Z
Dispensation category
B
First authorization
05/03/2020
Authorization expiration date
31/12/9999
IT number
01.99.0.
Domain
Human medicine
Field of application
Behandlung der Transthyretin-Amyloidose bei erwachsenen Patienten mit Wildtyp- oder hereditärer Kardiomyopathie

Packaging details

Description (FR)
VYNDAQEL caps moll 20 mg 30 pce
Description (DE)
VYNDAQEL Weichkaps 20 mg 30 Stk
Market launch
05/03/2020
Narcotic (BTM)
No